We argue against the recently published statement that tumor-specific molecular alterations found in "normal" prostate tissue from cancer patients challenge focal therapy approaches that only target a visible cancer lesion and not the adjacent molecular field.
Written by:
Schlomm T, Weischenfeldt J, Korbel J, Sauter G. Are you the author?
Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Genome Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Reference: Eur Urol. 2015 Apr 22. pii: S0302-2838(15)00314-0.
doi: 10.1016/j.eururo.2015.04.012
PubMed Abstract
PMID: 25913065